Download PDF
PSYCH up2date 2017; 11(04): 293-297
DOI: 10.1055/s-0043-112884
SOP / Arbeitsablauf
Georg Thieme Verlag KG Stuttgart · New York

SOP Lithiumaugmentation

Benjamin Ochs
,
Tom Bschor
Further Information

Publication History

Publication Date:
17 July 2017 (online)

Also available at
    Permissions and Reprints All articles of this category

Lithiumaugmentation ist eine additive, gut evaluierte Therapiemethode zur Behandlung akuter Depressionen. Sie wird für Patienten eingesetzt, die auf einen Therapieversuch mit einem Antidepressivum nicht angesprochen haben.
 

  • Literatur

  • 1 Burgess S, Geddes J, Hawton K. et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; (03) CD003013 DOI: 10.1002/14651858.CD003013.
    Google Scholar
  • 2 Severus E, Taylor MJ, Sauer C. et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; DOI: 10.1186/s40345-014-0015-8.
    Google Scholar
  • 3 Bauer M, Crossley NA, Gerber S, Bschor T. The Acute Antidepressive Effects of Lithium: From Monotherapy to Augmentation Therapy in Major Depression. In: Bauer M, Grof P, Müller-Oerlinghausen B. eds. Lithium in Neuropsychiatry. The Comprehensive Guide. London: Informa healthcare; 2006: 109-127
    CrossrefGoogle Scholar
  • 4 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940
    CrossrefGoogle Scholar
  • 5 Nelson JC, Baumann P, Delucchi K. et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168: 269-275
    CrossrefGoogle Scholar
  • 6 DGPPN, BÄK, KBV, AWMF, Hrsg. für die Leitliniengruppe Unipolare Depression*. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. 2. Auflage. Version 5. 2015. http://www.depression.versorgungsleitlinien.de Stand: 10.04.2017 (* Organisationen, die in der Leitliniengruppe kooperierten: DGPPN, BÄK,KBV, AWMF, ACKPA, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW, BDK, BDP, BPM, BVDN, BVDP, BVVP, CPKA, DÄVT, DFT, DGGPP, DGPT, DGVT, DPG, DPV, DPtV, DVT, GwG, Stiftung Deutsche Depressionshilfe)
    Google Scholar
  • 7 Dé Montigny C, Grunberg F, Mayer A. et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-256
    CrossrefGoogle Scholar
  • 8 Bschor T. Lithium in the treatment of major depressive disorder. Drugs 2014; 74: 855-862
    CrossrefGoogle Scholar
  • 9 Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64 (Suppl. 05) 44-52
    Google Scholar
  • 10 Cipriani A, Pretty H, Hawton K. et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
    CrossrefGoogle Scholar
  • 11 Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172
    CrossrefGoogle Scholar
  • 12 Bschor T, Bauer M. Is successful lithium augmentation limited to serotonergic antidepressants?. J Clin Psychopharmacol 2004; 24: 240-241
    CrossrefGoogle Scholar
  • 13 Bschor T, Berghöfer A, Ströhle A. et al. How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002; 22: 427-430
    CrossrefGoogle Scholar
  • 14 Bauer M, Bschor T, Kunz D. et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435
    CrossrefGoogle Scholar